ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Lexicon Pharmaceuticals, Inc." (LXRX) Report Updated: Sep 26, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Lexicon Pharmaceuticals, Inc." (LXRX)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Biotechnology
Competitors: MDVN,DMPI,MNOV,PIP

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: B down upgrade
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"Lexicon Pharmaceuticals, Inc."© quotemedia

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs include telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome. The company’s drug development programs also comprise Sotagliflozin, an orally-delivered small molecule drug candidate that has completed Phase II clinical trials to treat type 1 diabetes; and has completed two Phase II clinical trials to treat type 2 diabetes, as well as for the treatment of type 2 diabetes in patients with renal impairment. In addition, it develops LX1033, an orally-delivered small molecule compound, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound that has completed Phase II clinical trials to treat autoimmune disease; and LX7101, a topically-delivered small molecule compound that has completed Phase I clinical trials for the treatment of glaucoma. Further, the company’s preclinical development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has license and collaboration agreement with Ipsen Pharma SAS; and drug discovery alliance with Bristol-Myers Squibb Company and Genentech, Inc., as well as partnership with Sanofi to develop and commercialize Sotagliflozin to treat diabetes. The company was founded in 1995 and is headquartered in The Woodlands, Texas.